Xponance Inc. Sells 1,563 Shares of UiPath Inc. (NYSE:PATH)

Xponance Inc. cut its position in UiPath Inc. (NYSE:PATH) by 3.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,283 shares of the healthcare company’s stock after selling 1,563 shares during the quarter. Xponance Inc.’s holdings in UiPath were worth $1,075,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. CWM LLC raised its holdings in UiPath by 19.6% in the 3rd quarter. CWM LLC now owns 8,799 shares of the healthcare company’s stock valued at $151,000 after acquiring an additional 1,439 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in UiPath by 104.4% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 102,000 shares of the healthcare company’s stock valued at $1,745,000 after acquiring an additional 52,100 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in UiPath by 196.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 332,715 shares of the healthcare company’s stock valued at $5,693,000 after acquiring an additional 220,618 shares in the last quarter. Raymond James & Associates raised its holdings in UiPath by 51.0% in the 3rd quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock valued at $1,532,000 after acquiring an additional 30,244 shares in the last quarter. Finally, Bangor Savings Bank raised its holdings in UiPath by 4.0% in the 3rd quarter. Bangor Savings Bank now owns 62,893 shares of the healthcare company’s stock valued at $1,076,000 after acquiring an additional 2,406 shares in the last quarter. 62.50% of the stock is currently owned by institutional investors.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 16,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the transaction, the chief financial officer now directly owns 103,505 shares of the company’s stock, valued at approximately $2,325,757.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 72,000 shares of company stock worth $1,591,360 in the last 90 days. Corporate insiders own 31.03% of the company’s stock.

UiPath Stock Performance

Shares of UiPath stock opened at $19.69 on Thursday. UiPath Inc. has a one year low of $12.38 and a one year high of $27.87. The stock’s 50-day moving average is $22.42 and its 200 day moving average is $21.55.

UiPath (NYSE:PATH) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. Analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Mizuho lifted their price objective on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Thursday, March 14th. Barclays boosted their price objective on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Friday, March 15th. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of UiPath in a research report on Wednesday, March 20th. DA Davidson boosted their price objective on UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Finally, Bank of America boosted their price objective on UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.